Drug Profile
Antibody based therapeutics - Compugen/AstraZeneca
Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Compugen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Cancer in Israel (Parenteral)
- 21 Aug 2019 Phase-I clinical trials in Cancer in Israel (Parenteral) before August 2019 (Compugen Pipeline, August 2019)
- 02 Apr 2018 MedImmune in-licenses bi-specific and multi-specific Immuno-oncology antibody products from Compugen